Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2242-2249

  Hesketh, P ^a   Navari, R ^a   Grote, T ^a   Gralla, R ^a   Hainsworth, J ^a   Kris, M ^a   Anthony, L ^a   Khojasteh, A ^a   Tapazoglou, E ^a   Benedict, C ^a   Hahne, W ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOLASETRON MESILATE; ONDANSETRON;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 9444264707     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2242     Document Type: Article

References (34)

1. Hesketh PJ, Gandara DR: Serotonin antagonists: A new class of antiemetic agents. J Natl Cancer Inst 83:613-620, 1991
2. 3 antagonists incorporating a novel bridged pseudopelletierine ring system. Actual Chim Ther 16:187-189, 1989
3. Boxenbaum H, Gillespie T, Heck K, et al: Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693-701, 1992
4. 3 antagonists MDL 73147EF (dolasetron mesylate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells. Eur J Pharmacol 219:9-13, 1992
5. 3 receptor antagonist. Br J Pharmacol 107:449, 1992 (suppl; abstr)
6. Miller RC, Galvan M, Gittos MW, et al: Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 28:87-93, 1993
7. Shah A, Lanman R, Bhargava V, et al: Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 16:177-189, 1995
8. Galvan M, Gittos MW, Fatmi M: Dolasetron mesylate. Drugs Future 18:506-509, 1993
9. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 17:97-102, 1994
10. Kris MG, Grunberg SM, Gralla RJ, et al: Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049, 1994
11. Plezia P, Modiano M, Alberts D, et al: A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73,147EF in patients (PTS) receiving high dose cisplatin (CDDP)-containing chemotherapy (CT). Proc Soc Clin Oncol 11:1425, 1992 (abstr)
12. Hesketh PJ, Gandara DR, Hesketh AM, et al: Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 4:141-146, 1996
13. Tonato M, Roila R, Del Favero A: Methodology of antiemetic trials: A review. Ann Oncol 2:107-114, 1991
14. Cubeddu LX, Hoffman I, Fuenmayor NT, et al: Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810-816, 1990
15. Beck TM, Hesketh PJ, Madajewicz S, et al: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969-1975, 1992
16. Kris MG, Gralla RJ, Clark RA, et al: Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 60:2816-2822, 1987
17. Clark R, Tyson L, Frisone M: A correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER). Oncol Nurs Forum 12:96, 1985 (abstr)
18. Cox DR: Regression models and life tables. J R Soc Statistics 34:187-202, 1972
19. 3 receptor antagonists the same? Eur J Cancer Clin Oncol 28A:S2-6, 1992 (suppl 1)
20. Bonneterre J, Hecquet B, on behalf of the French Northern Oncology Group: Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Eur J Cancer Clin Oncol (in press)
21. Noble A, Bremmer K, Goedhals L, et al: A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety, and patient preference. Eur J Cancer Clin Oncol 30:1083-1088, 1994
22. Martoni S, Angelelli B, Guaraldi M, et al: Granisetron (GRA) vs ondansetron (OND) in the prevention of cisplatinum-induced emesis: An open randomized cross-over study. Am Soc Clin Oncol 13:431, 1993 (abstr)
23. Ruff P, Paska W, Goedhals L, et al: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre, double-blind, randomized, parallel-group study. Oncology 41:113-118, 1994
24. 3 receptors. Proc Soc Eur Med Oncol 17:204, 1994 (abstr)
25. Navari R, Gandara D, Hesketh P, et al: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248, 1995
26. Addelman M, Erlichman C, Fine S, et al: Phase I/II trial of granisetron: A novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 8:337-341, 1990
27. Williams PD, Cohen MI, Turk JA: Electrocardiographic effects of zatosetron and ondansetron, two 5-HT3 receptor antagonists, in anesthetized dogs. Drug Dev Res 24:277-284, 1991
28. Baltzer L, Pisters KMW, Kris MG, et al: High dose ondansetron (OND) plus dexamethasone (DEX) for the prevention of nausea and vomiting with multiple day cisplatin chemotherapy. Proc Am Soc Clin Oncol 12:462, 1993 (abstr)
29. Lifsey DS, Gralla RJ, Clark RA, et al: Electrocardiographic changes with serotonin antagonist antiemetics: Rate of occurrence and clinical relevance. Proc Am Soc Clin Oncol 12:463, 1993 (abstr)
30. Kasimis B, Tapazoglou E. Schulman P, et al: A double-blind, randomized study of two different dose regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high dose cisplatin (CDDP) chemotherapy. Proc Soc Clin Oncol 13:466, 1994 (abstr)
31. 3 antagonists ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol 113:527-535, 1994
32. c in man. Clin Res 39:718, 1991 (abstr)
33. Gralla RJ: Current issues in the management of nausea and vomiting. Ann Oncol 4:3-7, 1993 (suppl)
34. Du Bois A, Meerpohl HG, Vach W, et al: Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: A study of ondansetron. Eur J Cancer 28:450-457, 1992